Handberg J, Hansen S W
Finsencentret, Onkologisk afdeling, Rigshospitalet, København.
Ugeskr Laeger. 1996 Jul 15;158(29):4175-80.
This review deals with high-dose chemotherapy plus haematopoietic stem cell support as treatment to patients with chemosensitive solid tumours, breast-, testicular-, small cell lung-, and ovarian cancer. Dose-intensification of cytotoxic agents without stem cell support has not increased survival in these patients. High-dose chemotherapy plus stem cell support is a promising treatment strategy as adjuvant therapy in patients with high-risk breast cancer, i.e. more than 6-10 metastatic axillary lymph nodes, and there are several on-going randomized studies investigating conventional versus high-dose therapy in this situation both in Europe and in the US. Another international randomized study concerns patients with testicular cancer, where high-dose therapy is given as relapse treatment and as initial therapy in high-risk patients. High-dose therapy is an experimental treatment in all solid tumours, but there are no data supporting randomized studies in other solid tumours.
本综述探讨了大剂量化疗加造血干细胞支持作为化疗敏感实体瘤（乳腺癌、睾丸癌、小细胞肺癌和卵巢癌）患者的治疗方法。在没有干细胞支持的情况下增加细胞毒性药物的剂量强度并未提高这些患者的生存率。大剂量化疗加干细胞支持作为高危乳腺癌（即腋窝淋巴结转移超过6 - 10个）患者的辅助治疗是一种有前景的治疗策略，目前欧洲和美国都有几项正在进行的随机研究，比较这种情况下的传统疗法和大剂量疗法。另一项国际随机研究针对睾丸癌患者，在该研究中，大剂量疗法用于复发治疗以及高危患者的初始治疗。大剂量疗法在所有实体瘤中都是一种实验性治疗方法，但尚无数据支持在其他实体瘤中开展随机研究。
